Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: GlobeNewswire
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it will host an in-person and virtual investor event to discuss preliminary data from the ongoing Phase 1 clinical trial evaluating PYX-201 in multiple types of solid tumors. The event will be held on November 20, 2024, at 4:30 p.m. ET at Venue 42 by Convene, located at 5 Times Square in New York City. Virtual attendance is also available. Pyxis Oncology’s executive management team will be joined by the following physician thought leaders to discuss preliminary data from the Phase 1 trial: Anthony Tolcher, MD, FRCPC, FACP, Founder and Chief Executive Officer, NEXT OncologyGlenn Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program) and Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute, Associate Pro
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $7.00.MarketBeat
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock, down previously from $10.00.MarketBeat
- Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201GlobeNewswire
- CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares [Yahoo! Finance]Yahoo! Finance
PYXS
Earnings
- 11/12/24 - Miss
PYXS
Sec Filings
- 12/23/24 - Form SCHEDULE
- 12/23/24 - Form 4
- 12/23/24 - Form 4
- PYXS's page on the SEC website